FindTrial
Sign In

A medical economic analysis of cancer chemotherapy for patients with advanced lung cancer.

A medical economic analysis of cancer chemotherapy for patients with advanced lung cancer. - medical economic analysis of chemotherapy for patients with advanced lung cancer.

Status
Recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000042535
Enrollment
Unknown
Registered
2020-11-24
Start date
2020-11-24
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

None listed

Sponsors

kansai medical university
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Between June, 2020 to December, 2022, anti-cancer drugs for patients with lung cancer has been approved by Ministry of Health, Labor and Welfare, JAPAN

Exclusion criteria

Exclusion criteria: Between June, 2020 to December, 2022, anti-cancer drugs for patients with lung cancer hasn't been approved yet, or rescission of approval by Ministry of Health, Labor and Welfare, JAPAN

Design outcomes

Primary

MeasureTime frame
compare incremental cost effectiveness ratio between each drug as 1st-line or 2nd-line chemotherapy including molecular target drugs, angiogenesis inhibitors and immune checkpoint inhibitors for improving prognosis in patients with advanced lung cancer.—

Secondary

MeasureTime frame
search for appropriate treatment in cost-effectiveness for patients with advanced lung cancer, according to each of histopathological type, driver mutation and expression of PD-L1.—

Countries

Japan

Contacts

Public ContactTakeshi Tamaki

Kansai Medical University Medical Center First Department of Internal Medicine

tamakit@takii.kmu.ac.jp0669921001

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026